Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00GNK
|
||||
| Former ID |
DCL000156
|
||||
| Drug Name |
LY293111
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10:C25] | Discontinued in Phase 2 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Sawyer & Brooks
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C33H33FO6
|
||||
| InChI |
InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
|
||||
| InChIKey |
YFIZRWPXUYFCSN-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 161172-51-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Leukotriene B4 receptor 1 | Target Info | Antagonist | [3], [4], [5] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| Reactome | Leukotriene receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Spinal Cord Injury | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2948). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003262) | ||||
| REF 3 | Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia. 2005 Nov;19(11):1977-84. | ||||
| REF 4 | A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs. 2007 Jun;25(3):217-25. Epub 2006 Dec 5. | ||||
| REF 5 | The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096. Epub 2009 Jan 27. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.